Surveillance of drug prescribing: why outliers miss their targets – a qualitative study

Authors: Julia Gollnick, Nikoletta Zeschick, Franziska Hörbrand, Peter Killian, Maria Sebastiao, Thomas Kühlein, Norbert Donner-Banzhoff

Source: BMC Health Services Research, Vol 25, Iss 1, Pp 1-10 (2025)

Subject Terms: Drug prescriptions, Quality of health care/economics, Qualitative research, Drug costs, Clinical decision-making, Public aspects of medicine, RA1-1270

File Description: electronic resource

Relation: https://doaj.org/toc/1472-6963

Access URL: https://doaj.org/article/252027bb472249a0a698c79b74822819

Ten‐Year Medicare Use and Spending on the 10 Drugs Selected for Negotiation Under the Inflation Reduction Act

Authors: Mohammed Essa, Joseph S. Ross, Sanket S. Dhruva, Nihar R. Desai, Erica S. Spatz, Kamil F. Faridi

Source: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 14, Iss 3 (2025)

Subject Terms: cardiovascular diseases, drug costs, Medicaid, Medicare Part D, prescription drugs, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: https://doaj.org/toc/2047-9980

Access URL: https://doaj.org/article/1a85dff54c6343be903d813ff37ab802

Urologic Cancer Drug Costs in Low- and Middle-Income Countries

Authors: Lan Anh S. Galloway, Brian D. Cortese, Ruchika Talwar

Source: Société Internationale d’Urologie Journal, Vol 5, Iss 5, Pp 312-319 (2024)

Subject Terms: drug costs, LMICs, novel hormonal therapy, bladder cancer, Wilms tumor, Diseases of the genitourinary system. Urology, RC870-923

File Description: electronic resource

Relation: https://www.mdpi.com/2563-6499/5/5/50; https://doaj.org/toc/2563-6499

Access URL: https://doaj.org/article/315333753be64fa0ba188983ea24e561

Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model

Authors: Blommestein, Hedwig M. ^{a, ⁎}, de Groot, Saskia ^{a, b}, Leeneman, Brenda ^{a, b}, Uyl-de Groot, Carin A. ^{a, b}, Haanen, John B.A.G. ^c, Wouters, Michel W.J.M. ^{d, e, f}, Aarts, Maureen J.B. ^g, van den Berkmortel, Franchette W.P.J. ^h, Blokx, Willeke A.M. ⁱ, Boers-Sonderen, Marye J. ^j, van den Eertwegh, Alfons J.M. ^k, de Groot, Jan Willem B. ^l, Hospers, Geke A.P. ^m, Kapiteijn, Ellen ⁿ, van Not, Olivier J. ^{d, o}, van der Veldt, Astrid A.M. ^p, Suijkerbuijk, Karijn P.M. ^o, Franken, Margreet G. ^{a, b, 1}

Source: In European Journal of Cancer 11 March 2025 218

Out-of-pocket prescription medicine expenditure amongst community-dwelling adults: Findings from the Irish longitudinal study on ageing (TILDA) in 2016

Authors: Larkin, James ^{a, b}, Prendergast, Ciaran ^a, Murry, Logan T. ^a, Flood, Michelle ^a, Clyne, Barbara ^c, Burke, Sara ^d, Keegan, Conor ^e, Boland, Fiona ^f, Fahey, Tom ^b, Persaud, Nav ^{g, h}, Kenny, Rose Anne ⁱ, Moriarty, Frank ^{a, i, ⁎}

Source: In Exploratory Research in Clinical and Social Pharmacy March 2025 17

Cost-Related medication non-adherence in Pakistan: a pervasive public health challenge

Authors: Muhammad Fahad Iqbal Khan, Izhar Muhammad Shah, Shahzaib Khan

Source: Journal of the Pakistan Medical Association, Vol 75, Iss 02 (2025)

Subject Terms: Drug Costs, Medication Adherence, Prescription Fees, Healthcare costs, Resource-limited setting, Socioeconomic Factors, Medicine

File Description: electronic resource

Relation: https://jpma.org.pk/index.php/public_html/article/view/20817; https://doaj.org/toc/0030-9982

Access URL: https://doaj.org/article/d489fae9d1b74834a3c592a476a7a812

Catastrophic health expenditures incurred by families in 2003, 2009 and 2018 in the Federal District, Brazil: evolution and composition

Authors: Pedro Henrique Alves Santos, Theo da Fonseca Torres, Letícia Xander Russo, Everton Nunes da Silva

Source: Epidemiologia e Serviços de Saúde, Vol 33 (2025)

Subject Terms: Catastrophic Health Expenditure, Health Expenditure, Drug Costs, Health Care Economics and Organizations, Time Series Studies, Medicine, Public aspects of medicine, RA1-1270

File Description: electronic resource

Relation: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2237-96222024000100235&lng=en&tlng=en; http://www.scielo.br/pdf/ress/v33/2237-9622-ress-33-e20231358.pdf; https://doaj.org/toc/2237-9622

Access URL: https://doaj.org/article/26703b83c4a144a1bb74f446359557de

Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024

Authors: Stefan Kohler, Jay Achar, Christiaan Mulder, Norman Sitali, Nicolas Paul

Source: Globalization and Health, Vol 20, Iss 1, Pp 1-16 (2024)

Subject Terms: Cost analysis, Drug costs, Drug supply, Global Drug Facility, Price trends, Tuberculosis drugs, Public aspects of medicine, RA1-1270

File Description: electronic resource

Relation: https://doaj.org/toc/1744-8603

Access URL: https://doaj.org/article/ce1b657b1c804923a2395652b1d75e15

The association between multimorbidity and out-of-pocket expenditure for prescription medicines among adults in Denmark: A population-based register study

Authors: Larkin, James ^{a, ⁎}, Smith, Susan M. ^b, Christensen, Line Due ^c, Voss, Thomas Schmidt ^d, Vestergaard, Claus Høstrup ^c, Paust, Amanda ^c, Prior, Anders ^c

Source: In Research in Social and Administrative Pharmacy March 2025

Insurance coverage and access to gynecologic oncology: Where are we now

Authors: Mulugeta-Gordon, Lakeisha ^{a, b, c}, Smith, Anna Jo Bodurtha ^{a, b, c, d, ⁎}

Source: In Gynecologic Oncology January 2025 192:56-58

New Anticancer Drugs: Reliably Assessing 'Value' While Addressing High Prices

Authors: David J. Stewart, John-Peter Bradford, Sandeep Sehdev, Tim Ramsay, Vishal Navani, Nigel S. B. Rawson, Di Maria Jiang, Joanna Gotfrit, Paul Wheatley-Price, Geoffrey Liu, Alan Kaplan, Silvana Spadafora, Shaun G. Goodman, Rebecca A. C. Auer, Gerald Batist

Source: Current Oncology, Vol 31, Iss 5, Pp 2453-2480 (2024)

Subject Terms: drug costs, drug value, ICER, QALY, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.mdpi.com/1718-7729/31/5/184; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729

Access URL: https://doaj.org/article/e2a0bda42f934ee6ba8bb491b5743aa9

Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales

Authors: Yankier Pijeira Perez, Eifiona Wood, Dyfrig A Hughes

Source: Orphanet Journal of Rare Diseases, Vol 18, Iss 1, Pp 1-8 (2023)

Subject Terms: Orphan Drugs, Drug costs, Costs analysis, health economics, Medicine

File Description: electronic resource

Relation: https://doaj.org/toc/1750-1172

Access URL: https://doaj.org/article/be581134551441ebb3b366087c16bb91

Physicians’ assessment of the Bavarian drug-expenditure control system: a qualitative study

Authors: Nikoletta Zeschick, Julia Gollnick, Julia Muth, Franziska Hörbrand, Peter Killian, Norbert Donner-Banzhoff, Thomas Kühlein, Maria Sebastião

Source: BMC Health Services Research, Vol 23, Iss 1, Pp 1-12 (2023)

Subject Terms: Wirkstoffvereinbarung, Active substance agreement, Drug prescriptions, Economic efficiency, Drug costs, Public aspects of medicine, RA1-1270

File Description: electronic resource

Relation: https://doaj.org/toc/1472-6963

Access URL: https://doaj.org/article/4992d0fb8bb942e3a99e54af1b3497a2

Biosimilars in Europe

Contributors: Vulto, Arnold G., Simoens, Steven, Huys, Isabelle

Subject Terms: infliximab, etanercept, TNFα inhibitors, biologics, biosimilars, Germany, policies, incentives, uptake, market dynamics, biosimilar market, biosimilar/supply and distribution, biosimilar sustainability, Delphi technique, pricing, reimbursement, utilization, biosimilar, biological, information, education, communication, patient, Europe, adalimumab, biosimilarity assessment, quality attributes (QAs), potentially critical quality attributes (pCQAs), European public assessment reports (EPARs), clinical governance, Spain, barriers, regulatory, review, approval, clinical, queries, regulatory science, budget impact analysis, savings, pharmaceutical spending, cost containment, reference biological, competitive market, Belgium, trastuzumab, intravenous, subcutaneous, HER2-positive breast cancer, drug costs, healthcare costs, cost simulation, tender, procurement, off-patent, award criteria, switching, interchangeability, sustainability, competition, Medicine and Nursing, Manufacturing industries

File Description: image/jpeg

Access URL: https://directory.doabooks.org/handle/20.500.12854/96784
https://mdpi.com/books/pdfview/book/6730

Injectable antibiotic use in India: public-private share in volume and cost [version 1; peer review: 1 approved, 2 approved with reservations]

Authors: Shaffi Fazaludeen Koya, Katherine Klemperer, Senthil Ganesh, Anthony McDonnell, Prashant Yadav

Source: Wellcome Open Research, Vol 9 (2024)

Subject Terms: Antibiotic consumption, defined daily doses, antibiotic stewardship, drug utilization, drug costs., eng, Medicine, Science

File Description: electronic resource

Relation: https://wellcomeopenresearch.org/articles/9-70/v1; https://doaj.org/toc/2398-502X

Access URL: https://doaj.org/article/0b1d835548e14eaea890858d8de2cbb3

Evaluation of 340B prescription assistance program on healthcare use in chronic obstructive pulmonary disease

Authors: Leah M. Taliaferro, Sarah Dodson, Melissa C. Norton, Samuel Ofei-Dodoo

Source: Exploratory Research in Clinical and Social Pharmacy, Vol 11, Iss , Pp 100295- (2023)

Subject Terms: Drug costs, Pharmacy, Pulmonary disease, chronic obstructive, United States Health Resources and Services Administration, Vulnerable populations, 340B prescription assistance program, Pharmacy and materia medica, RS1-441

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2667276623000768; https://doaj.org/toc/2667-2766

Access URL: https://doaj.org/article/43f850c0f43f44c989c300695c7ebac4

The challenges of access to innovative medicines with limited evidence in the European Union

Authors: Antonio Vallano, Caridad Pontes, Antònia Agustí

Source: Frontiers in Pharmacology, Vol 14 (2023)

Subject Terms: drug approval, drug costs, orphan drug, antineoplastic agents, European Union, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2023.1215431/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/4d9e0b916ea04d04917560c32700cc5a

Profile of judicialization in access to antineoplastic drugs and their costs: a cross-sectional, descriptive study based on a set of all lawsuits filed between 2016 and 2018 in a state in the Northeast Region of Brazil

Authors: Fábio Henrique Cavalcanti de Oliveira, José Eudes de Lorena Sobrinho, Antônio da Cruz Gouveia Mendes, Haynne Magalhães Santos Gutman, Geraldo Jorge Filho, Ulisses Ramos Montarroyos

Source: BMC Public Health, Vol 22, Iss 1, Pp 1-10 (2022)

Subject Terms: Judicialization of healthcare, Pharmaceutical assistance, Antineoplastic drugs, Drug costs, Costs and cost analysis, Public aspects of medicine, RA1-1270

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2458

Access URL: https://doaj.org/article/37579ee0fb0e47bd8ffd6093ac1f10c7

Public procurement of antineoplastic agents used for treating breast cancer in Brazil between 2013 and 2019

Authors: Ranailla Lima Bandeira dos Santos, Vera Lúcia Edais Pepe, Claudia Garcia Serpa Osorio-de-Castro

Source: BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)

Subject Terms: Pharmaceutical services, Drug costs, Antineoplastic agents, Federal government, Breast neoplasms, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/1f8b62689db940d28fcffebfdfef6b05

Drug costs in context: assessing drug costs in cost-of-illness analyses

Authors: T Joseph Mattingly II, Shannon Weathers

Source: Drugs in Context, Vol 11, Pp 1-7 (2022)

Subject Terms: burden-of-illness, cost-of-illness, drug costs, pharmacoeconomics, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.drugsincontext.com/drug-costs-in-context-assessing-drug-costs-in-cost-of-illness-analyses; https://doaj.org/toc/1740-4398

Access URL: https://doaj.org/article/4f10474a347f484dac9e54021fadf7e2